conivaptan sold brand name vaprisol nonpeptide inhibitor receptor antidiuretic hormone also called vasopressin approved hyponatremia low blood sodium levels compound discovered astellas marked drug marketed cumberland pharmaceuticals inc conivaptan inhibits two three subtypes vasopressin receptor effectively causes iatrogenic nephrogenic diabetes insipidus conivaptan approved american food drug administration treatment decompensated congestive heart failure however theory vasopressin receptor antagonism would particularly useful setting initial study shows conivaptan commonly used hospital cases euvolemic hypervolemic hyponatremia conditions sodium level blood falls significantly normal united states hyponatremia affects four percent hospitalized patients although many patients show symptoms extreme cases may result brain swelling respiratory arrest even death hypervolemic hyponatremia specifically body serum sodium levels fall total body water increase results edema associated congestive heart failure liver disease kidney conivaptan hydrochloride arginine vasopressin avp receptor antagonist affinity human receptors nanomolar range vitro avp levels blood crucial water electrolyte regulation balance receptors maintain plasma osmolality coupled aquaporin channels collecting ducts kidneys regulate avp levels conivaptan hydrochloride functions antagonizing receptors renal collecting ducts thus causing aquaresis water secretion typical pharmacodynamic effects drug increase net fluid loss increase urine output decrease osmolality urine conivaptan inhibits metabolism body displaying nonlinear pharmacokinetics conivaptan found bound human plasma proteins range ngml ngml mean halflife drug hours mean clearance adverse reactions conivaptan found site infusion complications include blood lymphatic system disorders gastrointestinal disorders metabolism nutrition disorders psychiatric disorders well vascular risk rapid correction hyponatremia causing fatal osmotic demyelination conivaptan hydrochloride offwhite pale yellow power solubility mgml water injectable formulation consists mg conivaptan hydrochloride g ethanol g propylene glycol conivaptan hydrochloride discovered yamanouchi pharmaceuticals marketed astellas yamanouchi pharmaceuticals filed new drug application fda conivaptan hydrochloride treat hyponatremia february december yamanouchi received approval investigational hyponatremia treatment using conivaptan hydrochloride yamanouchi pharmaceuticals fujisawa pharmaceuticlas merged renamed astellas astellas gained fda approval conivaptan hydrochloride december marked drug brand name vaprisol march vaprisol also gained fda approval treatment hypervolemia hyponatremia october vaprisol gained approval dextrose premixed formulation treatment hyponatremia cumberland pharmaceuticals bought vaprisol astellas took full responsibility development marketing cumberland pharmaceuticals pharmaceutical company based nashville tennessee addition vaprisol cumberland produces acetadote caldolor kristalose omeclamox ethyol hepatoren boxban vasculan currently phase ii clinical trials protaban methotrexate totect waiting httpsenwikipediaorgwikiconivaptan